COVID-19 in liver transplant recipients: An initial experience from the U.S. epicenter

Abstract

There is tremendous concern in the liver transplant (LT) community about the COVID-19 pandemic caused by SARS-CoV-2. Limited data raises questions regarding risk and severity, management of immunosuppression and hepatic injury related to COVID-19. The state of New York, specifically New York City, has become the new epicenter of the pandemic. The Mount Sinai Hospital is a tertiary-care academic medical center that supports the Recanati/Miller Transplantation Institute. Herein, we describe our initial experience with COVID-19 in LT recipients.